Market Research Report
Systemic Scleroderma Treatment Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues), By Region, And Segment Forecasts, 2020 - 2027
|Systemic Scleroderma Treatment Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues), By Region, And Segment Forecasts, 2020 - 2027|
Published: November 11, 2020
Grand View Research, Inc.
Content info: 70 Pages
Delivery time: 2-10 business days
The global systemic scleroderma treatment market size is expected to reach USD 1.9 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 4.0% from 2020 to 2027. The market is largely attributable to the strong presence of therapies used off-label that include small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented space with multiple players. Johnson and Johnson Services, Inc. dominated the market with a share of 23.7% in the year 2019. United Therapeutics Corporation is the second biggest service provider in the space with a significant share in 2019. The other players such as F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, and Pfizer Inc. also have a significant share of the global market.
The on-label treatment is in the development phase. Major players with therapies undergoing clinical development are divided into two sorts. There are some developing new compounds, whereas certain other established players are seen repurposing their drugs (currently approved for other indications) for scleroderma use. In September 2019, Boehringer Ingelheim GmbH announced the U.S. FDA approval of Ofev for the treatment of interstitial lung disease in patients with systemic sclerosis.
Supplemental indication approval is one of the most common strategies adopted by pharmaceutical players thriving in the space. There are several pharmaceutical companies adopting strategies that favor the pharmaceutical industry in offsetting high development costs.
For instance, companies are developing promising product candidates such as Ziritaxestat, an autotaxin inhibitor from Galapagos NV in collaboration with Gilead Sciences, Inc. Furthermore, Horizon Therapeutics plc entered the space with the acquisition of Curzion Pharmaceuticals, Inc. in April 2020 that is developing HZN-825 and Tepezza.